ClinicalTrials.gg
TerminatedNCT02268201Updated Nov 1, 2024

A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule

A Phase 4 interventional study of Advagraf and Prograf in Kidney Transplant Recipients, sponsored by Astellas Pharma China, Inc.. Terminated at 7 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Astellas Pharma China, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment

Why this study was terminated
Due to difficulty enrolling patients

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Jul 2013, registered Oct 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

KTx recipients receiving cyclosporine-based immunosuppressive therapy, and in the opinion of the investigator would benefit from switch to a tacrolimus-based immunosuppression, will switch the immunosuppressive therapy to a tacrolimus-based one. Efficacy and safety of patients will be observed for 52 weeks.

Read the detailed description

The primary objective of this study is to compare the adherence of kidney transplant recipients treated with Prograf and Advagraf regimens.

The secondary objectives of this study are:

  • To compare the renal function (eGFR) in KTx recipients treated with Cyclosporine and Tacrolimus regimens.
  • To compare the QoL of KTx recipients treated with Cyclosporine and Tacrolimus regimens.
  • To compare the efficacy of Cyclosporine and Tacrolimus regimens in KTx recipients.
  • To compare the safety of Cyclosporine and Tacrolimus regimens in KTx recipients.
02

Conditions studied

  • Kidney Transplant Recipients

Keywords

  • tacrolimus
  • immunosuppressive therapy
03

In context

Lead sponsor

Astellas Pharma China, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients have received cyclosporine-based therapy for more than 6 months, and have maintained a stable regimen for at least 8 weeks before enrollment
  • The trough blood level of cyclosporine maintained at 50-200ng/ml at least 4 weeks before enrollment
  • SCr\< 200 μmol/l ( 2.3 mg/dl)
  • Females of must have a negative pregnancy test within 48 hrs prior to randomization and reliable methods of should be started 4 weeks prior to and during the whole study
  • Understand and sign the approved form

Exclusion criteria

Exclusion Criteria:

  • Patients who have had other solid organ transplantations
  • 24 hours proteinuria>2g
  • /ALT,SGOT/AST or total rising to more than double the normal level
  • Patients suffering from serious infection lesions
  • Patients have severe diarrhea or vomiting, peptic ulcer and/or defective absorption
  • Patients have severe heart, lung disease, abnormal glucose tolerance or malignant tumor history
  • Known to administration of Tacrolimus. Subject has known to tacrolimus, or any of the product
  • Pregnancy or lactating women
  • Patients have participated in another clinical trial in the past month
  • Patient refuses to sign form
  • Patient not willing to continue in the study and wants to withdraw from the study
  • Poor adherence or lost to follow-up
  • Violation of protocol
  • Severe adverse events occurred need to withdraw the study according to investigator's judgment
  • Pregnancy
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    ADV group

    Once daily

    Drug: Advagraf

  • Experimental
    PRG group

    Twice daily

    Drug: Prograf

Interventions

  • oral

    Also known as: Tacrolimus prolonged-release capsule

  • oral

    Also known as: Tacrolimus capsule

06

What researchers measure

Primary outcomes

  1. medication adherence

    VAS will be used to evaluate adherence between PRG and ADV

    Time frame: Up to 52 weeks after switching

Secondary outcomes

  1. endogenous creatinine clearance rate (Ccr)

    Time frame: Day 0, Week-1, Week2, Week-4, Week-8, Week-16, Week-24, Week36 and Week-52

  2. Calculated glomerular filtration rate

    Time frame: Day 0, Week-1, Week2, Week-4, Week-8, Week-16, Week-24, Week36 and Week-52

  3. blood lipids

    total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglyceride

    Time frame: Day 0, Week-1, Week2, Week-4, Week-8, Week-16, Week-24, Week36 and Week-52

  4. liver function (AST, ALT and bilirubin)

    Time frame: Day 0, Week-1, Week2, Week-4, Week-8, Week-16, Week-24, Week36 and Week-52

  5. fasting blood-glucose (FBG)

    Time frame: Day 0, Week-1, Week2, Week-4, Week-8, Week-16, Week-24, Week36 and Week-52

  6. Safety assessed by the incidence and severity of adverse events

    Time frame: Up to 52 weeks after switching

07

Study locations

7 sites
  • Beijing, China
  • Fuzhou, China
  • Guangzhou, China
  • Jinan, China
  • Nanchang, China
  • Shanghai, China
  • Xi'an, China
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2013 to primary completion in Mar 2015, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2014
First posted
Oct 20, 2014
StartActual
Jul 23, 2013
Primary completionActual
Mar 31, 2015
CompletionActual
Mar 31, 2015
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02268201
Responsible party
Sponsor
First posted
Oct 20, 2014
Start date
Jul 23, 2013
Primary completion
Mar 31, 2015
Completion
Mar 31, 2015
Last update
Nov 1, 2024

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion